In short
Clinical trials are investigating GRNA1599 in people with chronic hepatitis B. The study is looking at safety, tolerability, and early signs of effect in adults with this long-term liver infection. It is also checking how the study drug behaves in the body and whether it may help control the disease.
Key points
- GRNA1599 is being studied in a clinical trial for chronic hepatitis B, a long-term liver infection. The trial is in Phase 1/2, which means it is first checking safety and tolerability and then looking for early signs of benefit. Researchers are also measuring pharmacokinetics and pharmacodynamics, which show how the body handles the study drug and how the body responds. The main outcome is the number and severity of treatment-emergent side effects from baseline to Month 6. The study is authorised and plans to enroll 66 people.
Trial overview
The clinical trial for GRNA1599 is studying people with chronic hepatitis B, which is a long-lasting infection of the liver. The study title says it is looking at safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy in this condition.
Who the study is for
This trial is for people with chronic hepatitis B. The source data do not give more detailed rules about age limits, lab results, or other entry requirements.
The study is an interventional trial, which means researchers give the study treatment and then watch what happens. It is designed to help answer whether GRNA1599 can be studied further in this patient group.
What researchers are measuring
The main primary outcome is the incidence and severity of treatment-emergent adverse events (TEAEs) from baseline to Month 6. TEAEs are side effects or medical problems that start after treatment begins, or become worse after treatment starts.
The brief summary says the study will assess the safety and tolerability of single and multiple doses of GRNA1599. This means the researchers want to know not only whether the treatment can be given, but also how people handle it over time.
The trial also includes PK and PD measures. PK describes how the body absorbs, moves, and removes a treatment, while PD describes the body’s response to it.
Trial phase and design
The study is in Phase 1/2. Phase 1 studies usually focus on safety and tolerability, and Phase 2 studies look more closely at early signs that the treatment may help.
The trial is using intravenous infusion, which means the study drug is given into a vein. The source data do not provide more detail about the schedule, dose levels, or whether the study is randomized.
Study status and size
The trial status is Authorised. This means the study has been approved to proceed.
The planned enrollment is 66 people. This is a relatively small study, which is common for early-stage clinical research.